Sun Pharmaceutical Industries Limited (SUNPHARMA) — Corporate Action | 22 May 2025(2 announcements)

Sun Pharmaceutical reported a 17.3% rise in EBITDA to Rs 152,717 million and 19% growth in adjusted net profit to Rs 119,844 million for FY25, driven by 13.7% growth in India formulation sales and 17.1% growth in Global Specialty sales. The company proposed a final dividend of Rs 5.50 per share, adding to the interim dividend of Rs 10.50 for a total of Rs 16 per share, up from Rs 13.50 in FY24. Consolidated sales reached Rs 520,412 million, up 9% year-on-year, with a 29% EBITDA margin. R&D investment stood at Rs 32,484 million (6.2% of sales), supporting a robust pipeline including Leqselvi and Unloxcyt. The filing includes an unmodified audit opinion and details of exceptional items such as US restructuring and litigation charges.

Sun Pharmaceutical reported consolidated sales of Rs 520,412 million, up 9% YoY, with EBITDA rising 17.3% to Rs 152,717 million and adjusted net profit up 19% to Rs 119,844 million. The company proposed a final dividend of Rs 5.50 per share, adding to the interim dividend for a total of Rs 16 per share. Global Specialty sales grew 17.1% to US$ 1,216 million, now representing 19.7% of total sales. R&D investment reached Rs 32,484 million (6.2% of sales), supporting a robust pipeline including Leqselvi and Unloxcyt. The 33rd AGM is scheduled for 31 July 2025 via videoconferencing.